Industry Outlook
The recombinant plasma protein therapeutics market is set to grow from US$ 7,788.9 Mn in 2017 to US$ 15,910.5 Mn in 2026 expanding at an annual growth rate of 8.3% during the forecast period from 2018 to 2026. According to World Federation of Hemophilia (WFH), approximately 1 in 1,000 people worldwide suffer with some form of bleeding disorder, 75% of them gain inadequate treatment and remain undiagnosed.
Market Synopsis
Get a sample copy for more information
"Lack of blood borne transmission disease and less severe effects in comparison to desmopressin popularizes recombinant coagulation factor VIII in treating hemophilia A"
Recombinant coagulation factor VIII is leading the drug class segment for recombinant plasma protein therapeutics market. It is preferred over human plasma derive products to avoid potential transmission of blood borne infections. It is replacing desmopressin in treating mild hemophilia due to less adverse effects. Recombinant factor IX will gain growth momentum in the near future owing to recent FDA approval of Rebinyn (Novo Nordisk) for long term treatment of hemophilia B.
Get a sample copy for more information
"Ability to adapt growth conditions in serum free suspension, powerful gene amplification system and capacity for post translational modification drive the Chinese hamster ovary cell lines in recombinant protein synthesis"
Since last 2 decades Chinese hamster ovarian cell lines have gained immense popularity over other cell lines such as baby hamster kidney cell lines and human embryonic kidney cell lines. Its ability to adapt growth conditions in serum free suspension, powerful gene amplifications and capacity for post translational modification proves its popularity as the most demanding cell line over others in recombinant protein syntheis.
Get a sample copy for more information
"High prevalence rate and 70 % of the diagnosed patients reported to suffer with severe form drive Hemophilia A market growth"
Hemophilia A also known as clotting factor VIII deficiency or classical hemophilia is currently leading the indication segment for recombinant plasma protein therapeutics market. It has a high prevalence rate of 1 in 5000 people with approximately 70% diagnosed patients reported to be suffering with severe form of hemophilia A. The other type is Hemophilia B which is less common form with an occurrence rate of 1 in 25,000 people, it is caused due to lack of clotting factor IX. Von Willebrand disease is keen to register impressive growth in the near future due to high occurrence in blood group O type and rising public health awareness.
"Rising prevalence of Hemophilia A and presence of a comprehensive network of federally funded treatment centers for hemophilia drive market growth in North America"
North America is reigning the regional segment for recombinant plasma protein therapeutics market with a share of 40%. The chief factors controlling its market growth are rising prevalence of hemophilia A, according to the research findings of Center for Disease Control and Prevention (CDC), approximately 20,000 people are suffering with hemophilia in the United States. The existence of a comprehensive network of federally funded treatment centers for hemophilia cater to the medical aid of 70% patients with blood clotting disorders in North America region. Europe accounts for 30% market share due to increasing new born babies suffering with hemophilia. According to European Medical Agency (EMA) research findings annually 400 babies are born with hemophilia. Domicile of major players such as Novo Nordisk A/S, Bayer AG, Shire, Plc etc. bolster the market growth in Europe. Asia Pacific holds 20% market growth and is keen to register rapid growth during the forecast period owing to adoption of recombinant technology for protein synthesis and large patient pool suffering with blood clotting disorders.
Historical & Forecast Period
This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.
Report Scope by Segments
Recombinant plasma protein therapeutics market segmentation is as follows:
| ATTRIBUTE |
DETAILS |
| Research Period |
2017-2027 |
| Base Year |
2018 |
| Forecast Period |
2019-2027 |
| Historical Year |
2017 |
| Unit |
USD Million |
| Segmentation |
By Drug Class (2016–2026; US$ Mn)
• Recombinant Factor VIII
• Recombinant Factor IX
|
|
By Cell Line (2016–2026; US$ Mn)
• Chinese Hamster Ovary
• Baby Hamster Kidney
• Human Embryonic Kidney
• Other
|
|
By Indication (2016–2026; US$ Mn)
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Other
|
|
Geography Segment (2016–2026; US$ Mn)
• North America (U.S., Canada)
• Europe (U.K., Germany, Rest of Europe)
• Asia Pacific (China, Japan, Rest of Asia Pacific)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Middle East and Africa (GCC, Rest of MEA)
|
Biotechnology companies manufacturing recombinant plasma proteins are Aptevo Therapeutics, Bayer AG, Bioverativ Therapeutics, Inc., CSL Behring, Novo Nordisk A/S, Octapharma, Plc., Pfizer, Inc., Pharming Group NV, Shire, Plc. and Viropharma Biologics, Inc.
Key questions answered in this report
- Which biotechnology companies are manufacturing recombinant coagulation factors?
- Why is recombinant coagulation factors replacing human plasma derive proteins and desmopressin in treating hemophilia A?
- What is the disease etiology and treatment regimen for Von Willebrand disease?
- Which factors make Chinese hamster ovary the most popular cell line in comparison to other cell lines?
- What will be the market trend in the developed and developing nations during the forecast period concerning the market growth of recombinant plasma protein therapeutics?
